Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx Corporation (Nasdaq: LUNG) presented long-term data from the TRANSFORM study at the ATS 2021 International Conference, highlighting the sustained benefits of the Zephyr® Endobronchial Valve in patients with severe COPD/emphysema. The results indicate significant improvements in lung function, quality of life, and exercise capacity for up to 24 months post-treatment. This minimally invasive procedure, offering a viable alternative to major surgery, has treated over 20,000 patients globally, showcasing its acceptance in clinical guidelines.
Pulmonx Corporation (Nasdaq: LUNG) reported a 7% increase in worldwide revenue to $9.2 million for Q1 2021, with a gross margin improvement to 71.5%. U.S. revenue declined 5% to $4.3 million, while international revenue surged 20% to $5.0 million. Operating expenses rose 59% to $18.6 million, leading to a net loss of $12.0 million or $0.34 per share. The company raised its 2021 revenue outlook to $48-$50 million, representing 47%-53% growth year-over-year, despite ongoing COVID-19 uncertainties.
Pulmonx Corporation (Nasdaq: LUNG) announced the appointments of Michael Ryan as Vice President of Corporate Strategy and Business Development, David Lehman as General Counsel, and Mahtab Fatemi as Vice President of Regulatory Affairs and Quality Assurance. Ryan joins from Boston Scientific, bringing extensive experience in business development within the pulmonary sector. Lehman has nearly two decades of legal expertise in the medical device industry, while Fatemi has over 20 years of regulatory experience in medical devices and pharmaceuticals. These appointments aim to strengthen Pulmonx's market position.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 am PT / 11:00 am ET. A live and archived webcast will be available in the Investors section of the Pulmonx website.
The company’s Zephyr® Endobronchial Valve and related systems are crucial for treating severe emphysema/COPD patients. The Zephyr Valve is FDA-approved and used in over 25 countries, with more than 80,000 valves deployed.
Pulmonx Corporation (NASDAQ: LUNG) will announce its Q1 2021 financial results on May 4, 2021, after trading closes. Management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can listen in by calling (833) 614-1518 for domestic or (270) 823-1072 for international participants, using Conference ID: 6696232. Pulmonx is known for its minimally invasive treatments for lung diseases, including its Zephyr® Endobronchial Valve, which is available in over 25 countries and has been used in more than 80,000 devices to treat over 20,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) reported a full year 2020 revenue of $32.7M, a marginal increase of 0.4% year-over-year. U.S. revenue surged 51% to $16.2M, while international revenue fell 24% to $16.5M. The fourth quarter saw total revenue decline 5% to $9.8M. Operating expenses spiked 41% to $16.4M, resulting in a net loss of $9.3M. Looking ahead, the company expects 2021 revenue between $46M and $50M, reflecting 41%-53% growth.
Pulmonx Corporation (NASDAQ: LUNG) will release its financial results for Q4 and full year 2020 on March 2, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company focuses on minimally invasive treatments for severe emphysema, with its Zephyr® Endobronchial Valve approved by the FDA as a breakthrough device. The valve has been utilized in over 20,000 patients worldwide. For more details, visit their investor webpage.
On January 28, 2021, JTV, a national jewelry retailer, announced its partnership with the Respiratory Health Association and Pulmonx Corporation for the third annual Catch Your Breath® campaign. This initiative aims to raise awareness and funds for women's lung disease during February 2021, focusing on educational opportunities about lung health. The campaign includes a special event from January 29 to 31, where 50% of sales from the Catch Your Breath® butterfly jewelry collection will benefit lung health programs.
Pulmonx Corporation (NASDAQ: LUNG) has welcomed Georgia Garinois-Melenikiotou and Thomas W. Burns to its Board of Directors as part of its initial public offering in October 2020. Garinois-Melenikiotou brings significant experience in global consumer marketing from her tenure at Estée Lauder and Johnson & Johnson, while Burns offers over 25 years of experience in medical technology, currently serving as CEO of Glaukos Corporation. Their expertise is expected to enhance Pulmonx's efforts in expanding its market presence for innovative treatments for severe lung disease.
Pulmonx Corporation announced that over 20,000 patients have been treated globally with its Zephyr® Endobronchial Valves, the first FDA-approved minimally invasive treatment for severe emphysema. This treatment significantly improves lung function, exercise capacity, and overall quality of life without the risks associated with traditional surgery. Dr. D. Kyle Hogarth highlighted the Zephyr Valve's role in helping patients breathe easier. The device is now included in national and global COPD treatment guidelines, evidencing its acceptance and effectiveness in clinical practice.